Full-Time

Senior Graphic Designer

Multimedia Marketing

Confirmed live in the last 24 hours

Biorender

Biorender

201-500 employees

Online platform for creating scientific illustrations

No salary listed

Senior

Remote in USA + 1 more

More locations: Remote in Canada

Remote-first with plans to bring everyone together at the Toronto office a few times each year.

Category
Graphic Design
Art, Graphics & Animation
Required Skills
Adobe Creative Suite
Adobe Photoshop
Adobe After Effects
Figma
Graphic Design
Requirements
  • 5+ years of experience at a fast-paced Saas / PLG company
  • Proven experience in creating multimedia content (a plus if it’s in the science industry)
  • Expert in Adobe Creative Suite (Illustrator, Photoshop, After Effects, Premiere Pro) and other relevant design tools (Figma, Cava, etc.)
  • Ability to analyze selling points or software features and translate them into compelling visual stories through quick, engaging visuals
  • Strong portfolio showcasing multimedia design work, including graphics for social media platforms, GIFs, and videos, particularly in scientific contexts.
Responsibilities
  • Design and produce multimedia content pieces that align with BioRender’s brand and marketing strategy
  • Create platform-specific graphics and multimedia content, including LinkedIn posts, Instagram Reels, Reddit graphics, 1-pagers, GIFs, videos, etc. ensuring high quality and brand consistency
  • Collaborate with the marketing and other teams to ensure all content is accurate and engaging, meeting project deadlines consistently
  • Develop and maintain a library of reusable design assets and templates to streamline content creation processes within X months
  • Create multimedia graphics for high-impact campaigns that boosts engagement and brand recognition
Desired Qualifications
  • Experience in the science industry is a plus

BioRender provides an online platform for creating and sharing scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform is designed to simplify the illustration process, making it easier for clients such as academic researchers, pharmaceutical companies, and educational institutions to create figures for research papers, presentations, and educational materials. BioRender operates on a subscription-based model, offering various plans that cater to different user needs, including enterprise solutions for larger organizations. The company's goal is to streamline the creation of scientific figures, saving users time and effort while enhancing the quality of scientific communication.

Company Size

201-500

Company Stage

Series A

Total Funding

$17.2M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for visualization tools due to complex research topics like mutant proteins.
  • Growing interest in graphical abstracts enhances research visibility and engagement.
  • Rise of remote work models boosts demand for digital collaboration tools like BioRender.

What critics are saying

  • AI-driven design tools could reduce demand for BioRender's platform.
  • Increased competition from lower-cost visualization platforms may impact market share.
  • Rapid tech advancements may require costly updates to BioRender's platform.

What makes Biorender unique

  • BioRender offers a vast library of pre-drawn icons from over 30 life sciences fields.
  • The platform provides a user-friendly interface for creating professional scientific figures quickly.
  • BioRender's subscription model offers various plans, catering to diverse client needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

5%

2 year growth

5%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.